Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus

Patent metadata

Field	Value
Publication number	US-11400150-B2
Application number	US-202016952864-A
Country	US
Kind code	B2
Filing date	Nov 19, 2020
Priority date	Jan 10, 2002
Publication date	Aug 2, 2022
Grant date	Aug 2, 2022

Abstract

The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines,

First claim

What is claimed is:

1. A method of inducing an immune response in a subject, comprising administering to the subject an immunogenic composition comprising about 100 to about 100,000 PFU of a virus chimera comprising a first nucleotide sequence encoding a premembrane/membrane (prM) protein and an envelope (E) protein from a West Nile virus, and a second nucleotide sequence encoding a capsid (C) protein and nonstructural proteins from a dengue type 4 virus and the 3′ untranslated region of the dengue type 4 genome comprising a deletion of about 30 nucleotides between nucleotides 10478-10507 corresponding to the TL2 stem-loop structure.

2. The method of claim 1 , wherein the method comprises administering the immunogenic composition to the subject subcutaneously.

3. The method of claim 1 , wherein the method comprises administering one to five doses of the immunogenic composition to the subject.

4. The method of claim 1 , wherein the subject is a human.

5. The method of claim 1 , wherein the subject is a non-human primate.

6. The method of claim 1 , wherein the subject is a bird or a horse.

7. The method of claim 1 , wherein the immunogenic composition further comprises an adjuvant.

8. The method of claim 1 , wherein the West Nile virus is strain NY99.

9. The method of claim 1 , wherein the virus chimera comprises a cleavage site joining the dengue virus capsid protein and the West Nile virus prM protein, and wherein the West Nile virus prM protein contains aspartic acid (Asp)at a position 3 amino acids downstream of the cleavage site and contains threonine (Thr) at a position 6 amino acids downstream of the cleavage site, wherein the cleavage site corresponds to amino acid position 3 of SEQ ID NO: 3.

Assignees

• Us Health
• Us Gov Sec Army

Inventors

• Pletnev Alexander G
• Putnak Joseph R
• Chanock Robert M
• Murphy Brian R
• Whitehead Stephen S
• Blaney Joseph E

Classifications

• C12N15/86

  Viral vectors · CPC title

• C12N2770/24122

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

• A61P31/12

  Antivirals · CPC title

• C07K14/005

  from viruses · CPC title

• A61K2039/5254

  avirulent or attenuated · CPC title